Uroflowmetry and Nocturnal Enuresis

NCT ID: NCT07028645

Last Updated: 2025-06-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-20

Study Completion Date

2025-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the uroflowmetry parameters of patients which were treated for enuresis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of approximately 100 patients with enuresis will be evaluated retrospectively. Uroflowmetry parameters of these patients will be evaluated. For this purpose, patients will be divided to mainly three groups according to the treatment choices.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Enuresis, Nocturnal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Desmopressin 120mcg

Patients treated with desmopressin 120 mcg

desmopressin melt form 120 μg

Intervention Type DRUG

Desmopressin 120 mcg will be used frist-line drug in the treatment of enuresis.

Desmopressin 240 mcg

Patients treated with desmopressin 240mcg

Desmopressin lyophilisate (Melt)

Intervention Type DRUG

Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg.

Desmopressin 240 mcg + anticholinergic

Patients treated with desmopressin 240mcg + anticholinergic agent

Propiverine tablet

Intervention Type DRUG

Propiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

desmopressin melt form 120 μg

Desmopressin 120 mcg will be used frist-line drug in the treatment of enuresis.

Intervention Type DRUG

Desmopressin lyophilisate (Melt)

Desmopressin 240 mcg will be used for the patients who have not responsive to desmopressin 120 mcg.

Intervention Type DRUG

Propiverine tablet

Propiverine (a dose of 0.8 mg/ kg) will be used for the patients who have -response to treatment with desmopressin 240 mcg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Presence of enuresis nocturna
* Patients who have uroflowmetry test

Exclusion Criteria

* Presence of lower urinary tract symptoms
* Presence of anatomical or neurological problems
* Patients with missing data
Minimum Eligible Age

5 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Furkan Adem Canbaz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Furkan Adem Canbaz

Medical doctor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sancaktepe Sehit Prof dr Ilhan Varank Training and Research Hospital

Istanbul, Kadikoy, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Kang BJ, Chung JM, Lee SD. Evaluation of Functional Bladder Capacity in Children with Nocturnal Enuresis According to Type and Treatment Outcome. Res Rep Urol. 2020 Sep 15;12:383-389. doi: 10.2147/RRU.S267417. eCollection 2020.

Reference Type BACKGROUND
PMID: 32984086 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ivstrh - UF PMNE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Overactive Bladder Syndrome
NCT05151081 COMPLETED
Desmopressin Response in the Young
NCT00230594 COMPLETED PHASE3